Application of the calcimimetic agent Etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients

Calcium sensitive receptor is an important target for treating secondary hyperparathyroidism (SHPT) of end-stage renal diseases. Etelcalcetide is a novel injectable calcimimetic agent, and in this article a comprehensive analysis was performed for its efficacy, adverse reactions, pharmacological properties and expected prognosis for the treatment of SHPT in hemodialysis patients. After retrieving and analyzing the data of clinical trials and animal experiments of Etekalcetide uhich carried out home and abrood,we fourd that, Etelcalcetide could significantly reduce the serum parathyroid hormone (PTH) in hemodialysis patients, and the indexes of fibroblast growth factor 23 (FGF-23) and serum calcium. However, there is still less evidence for long-term prognosis indices such as cardiovascular events, mortality, fractures and vascular calcification. Common drug-associated adverse reactions include asymptomatic hypocalcemia, vomiting, nausea, symptomatic hypocalcemia, and intravenous injection is unlikely to mitigate the gastrointestinal adverse effects. In conclusion, Etelcalcetide can be used to treat secondary hyperthyroidism in adult hemodialysis patients. However, the long-term prognosis of the patients should be further investigated.